MaxCyte, Inc.
("MaxCyte" or the "Company")
Exercise of options and PDMR
dealing
ROCKVILLE, MD, November 6, 2024: MaxCyte
Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering
focused company providing enabling platform technologies to advance
the discovery, development, and commercialization of
next-generation cell therapeutics and to support innovative,
cell-based research, announces that on 5 November 2024, as per a
filing lodged with the U.S. Securities and Exchange Commission,
Stanley Erck, a Non-Executive Director of the Company, exercised
options over 47,689 shares of common stock of $0.01 of the Company
("Common Stock") ("Exercise") in aggregate. The 47,689 new shares
of Common Stock were issued pursuant to the Company's existing its
block admission facility and were sold by Stanley Erck at a price
range between $3.610 and $3.755 per Common Stock ("Sale"). The sold
shares represent approximately 8.04% of Stanley Erck's total equity
and option holdings in the Company's stock capital,
respectively.
Following the Exercise and Sale,
Stanley Erck holds 247,751 shares of Common Stock representing 0.2%
of the issued stock capital of the Company. Following the Exercise,
Stanley Erck holds a further 276,501 options over Common Stock and
21,367 restricted stock units.
The sales and option exercises were
effected pursuant to a Rule 10b5-1 trading plan adopted by Stanley
Erck on 12 March 2024 relating solely to the sale of shares
acquired from exercise of options that expire on 11 November
2024.
MaxCyte
Contacts:
US IR
Adviser
Gilmartin
Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
Nominated Adviser and Joint
Corporate Broker
Panmure
Liberum
Emma Earl / Freddy
Crossley
Corporate
Broking
Rupert
Dearden
+44 (0)20 7886 2500
UK IR
Adviser
ICR
Healthcare
Mary-Jane Elliott
Chris
Welsh
+44 (0)203 709 5700
maxcyte@icrhealthcare.com
About
MaxCyte
At
MaxCyte, we pursue cell engineering excellence to maximize the
potential of cells to improve patients' lives. We have spent more
than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com and
follow us on X (formerly Twitter) and LinkedIn.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY
PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Stanley Erck
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte, Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Exercise of Options over
common stock
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Exercise Price(s)
|
Volume(s)
|
|
|
|
|
$0.040
|
47,689
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
47,689
|
|
|
|
|
- Price
|
$0.040
|
|
|
|
|
e)
|
Date of the transaction
|
1 November 2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Stanley Erck
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte, Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Sale of common stock
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Exercise Price(s)
|
Volume(s)
|
|
|
|
|
$3.6100
|
100
|
|
|
|
|
$3.6400
|
100
|
|
|
|
|
$3.6450
|
200
|
|
|
|
|
$3.6500
|
1500
|
|
|
|
|
$3.6550
|
1370
|
|
|
|
|
$3.6600
|
500
|
|
|
|
|
$3.6650
|
290
|
|
|
|
|
$3.6700
|
774
|
|
|
|
|
$3.6750
|
780
|
|
|
|
|
$3.6800
|
550
|
|
|
|
|
$3.6850
|
1150
|
|
|
|
|
$3.6900
|
650
|
|
|
|
|
$3.6950
|
3312
|
|
|
|
|
$3.7000
|
5910
|
|
|
|
|
$3.7050
|
1626
|
|
|
|
|
$3.7100
|
888
|
|
|
|
|
$3.7150
|
1375
|
|
|
|
|
$3.7200
|
5460
|
|
|
|
|
$3.7250
|
330
|
|
|
|
|
$3.7300
|
4667
|
|
|
|
|
$3.7350
|
675
|
|
|
|
|
$3.7400
|
6010
|
|
|
|
|
$3.7450
|
795
|
|
|
|
|
$3.7500
|
7297
|
|
|
|
|
$3.7550
|
1380
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
47,689
|
|
|
|
|
- Price
|
$3.7157
|
|
|
|
|
e)
|
Date of the transaction
|
1 November 2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|